Physician profile
Scott Salomone
NPI 1386178481
$4,354.75
in general payments reported to CMS, 2019-2025
17 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $519 · 2023: $1,161 · 2024: $1,088 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,520.10 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,150.68 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $635.02 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $614.51 | 2021-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $565.57 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $261.07 | 2022-2025 | Auvelity |
| Lundbeck LLC | $211.99 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.35 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $174.90 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $169.21 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $84.44 | 2022-2025 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $74.83 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $52.13 | 2022-2024 | Fanapt |
| Bausch Health US, LLC | $47.68 | 2022-2024 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $43.98 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.24 | 2021-2025 | Trintellix |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $19.34 | 2025 | Sublocade |
| Merck Sharp & Dohme LLC | $13.81 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Salomone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.